Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1059 views | HTML 1675 views | ?
Monika Toma1, Monika Witusik-Perkowska2, Marzena Szwed3, Robert Stawski4, Janusz Szemraj2, Malgorzata Drzewiecka1, Margaret Nieborowska-Skorska5, Maciej Radek6, Pawel Kolasa7,8, Ksenia Matlawska-Wasowska9, Tomasz Sliwinski1 and Tomasz Skorski5
1Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
2Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland
3Department of Medical Biophysics, University of Lodz, Lodz, Poland
4Department of Clinical Physiology, Medical University of Lodz, Lodz, Poland
5Department of Microbiology and Immunology, Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA
6Department of Neurosurgery, Surgery of Spine and Peripheral Nerves, Medical University of Lodz, University Hospital WAM-CSW, Lodz, Poland
7Department of Neurosurgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
8Social Sciences Academy in Lodz, Lodz, Poland
9Division of Pediatric Research, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
Tomasz Sliwinski, email: [email protected]
Tomasz Skorski, email: [email protected]
Keywords: glioblastoma; PARP inhibitor; LIG4; alkylating agent; synthetic lethality
Received: June 30, 2018 Accepted: November 16, 2018 Published: December 07, 2018
Cancer cells often accumulate spontaneous and treatment-induced DNA damage i.e. potentially lethal DNA double strand breaks (DSBs). Targeting DSB repair mechanisms with specific inhibitors could potentially sensitize cancer cells to the toxic effect of DSBs. Current treatment for glioblastoma includes tumor resection followed by radiotherapy and/or temozolomide (TMZ) – an alkylating agent inducing DNA damage. We hypothesize that combination of PARP inhibitor (PARPi) with TMZ in glioblastoma cells displaying downregulation of DSB repair genes could trigger synthetic lethality. In our study, we observed that PARP inhibitor (BMN673) was able to specifically sensitize DNA ligase 4 (LIG4)-deprived glioblastoma cells to TMZ while normal astrocytes were not affected. LIG4 downregulation resulting in low effectiveness of DNA-PK–mediated non-homologous end-joining (D-NHEJ), which in combination with BMN673 and TMZ resulted in accumulation of lethal DSBs and specific eradication of glioblastoma cells. Restoration of the LIG4 expression caused loss of sensitivity to BMN673+TMZ. In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.